The Effect of Growth Hormone in Assisted Reproductive Technology Clinical Outcome of Poor Responder

NCT ID: NCT03027843

Last Updated: 2017-01-23

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-03-31
• Study Completion Date: 2020-04-30

Brief Summary

Assisted reproduction treatment in patients with low ovarian reserve is a big difficult clinical problem. Growth hormone (GH) is crucial in the development of follicles since preantral follicle to ovulation and can promote steroid hormones and gamete formation, increase the granular cell sensitivity,and inhibition of follicular atresia. Latest research shows that GH can improve egg quality through regulating mitochondrial function of the oocytes and increase the rate of embryo euploid. It becomes a new argument in that promotion of clinical pregnancy rate in assisted reproduction treatment. GH applied in the field of assisted reproduction 30 years experience of applicable people, but drug dosage, drug intervention time continue to explore. 2015 China assisted reproductive stimulate ovulation medicine expert consensus recommend joint GH for poor ovarian response, repeated implantation failure patients and older patients assisted fertility treatment, but not on the specific use time limit, the daily dose of drugs and curative effect. How to maximize growth hormone potential advantage in improving the egg quality bothers the clinical doctors. We had a self-controlled retrospective analyses in growth hormone application and found that the average daily injections of GH dose 2 iu for 45 days can significantly improve the embryo quality in patients with low ovarian reaction. And now long-acting recombinant human growth hormone is available, which make it convenient for patients. A forward-looking experimental is expected to answer clinical practical problems and provide proper GH regimen for low ovarian responder.

Detailed Description

This study is a pilot study to investigate the effect of growth hormone in assisted reproductive technology clinical outcome of poor responder.

Design: randomized controlled trial. Setting: Assisted reproductive technologies unit. Patients: patients diagnosed poor ovarian responder who is in accordance with the inclusion criteria, and not meet the exclusion criteria, who had repeated IVF treatment from Mar 2017 to Aug 2019.

Intervention: The comparison was made between GH group and the control group, both groups are conducted with the mini-dose GnRH-a long protocol for IVF treatment. GH group use Long-acting recombinant human growth hormone 14IU qw, until the day of hCG.

Main outcome measures: The primary outcome of the study is live birth rate. The secondary outcomes were clinical pregnancy rate, number of oocytes retrieved, fertility rate, normal fertilization rate, rate of transferable embryo and good quality embryo rate.

Conditions

Low Ovarian Reserve

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

GH group

patients in group mini-dose GnRH-a long protocol combine with growth hormone

Group Type: ACTIVE_COMPARATOR

Growth Hormone

Intervention Type: DRUG

in GH group, patients have weekly injections of GH dose 14 iu, until the day of hCG.

control group

patients in group mini-dose GnRH-a long protocol without growth hormone

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Growth Hormone

in GH group, patients have weekly injections of GH dose 14 iu, until the day of hCG.

Intervention Type: DRUG

Other Intervention Names

somatotropin;GH;somatotrophin;somatotropic

Eligibility Criteria

Inclusion Criteria

1. Women age ≥35 years and ≤40 years.

2. 2≤ AFC≤6, and AMH level ≥0.5 and≤ 1.1 ng/ml.

3. Previous failed transfer cycle ≥2

4. Didn't participate in other clinical subjects in three months.

5. Written informed consent.

4. Patients request withdrawal and exit the trial because adverse events occur during the trial.

5. No record about treatment.

Exclusion Criteria

1. Body mass index (BMI) ≥25 kg/m2.

2. Endocrine metabolic disease, such as diabetes, insulin resistance, hyperthyroidism, Cushing's syndrome, hyperprolactinemia.

3. Hypertension (systolic blood pressure ≥140mmHg and diastolic blood pressure≥90mmHg.

4. Autoimmune diseases was definitively diagnosed, such as systemic lupus erythematosus, Sjogren's syndrome, Hashimoto's Thyroiditis, multiple sclerosis, rheumatoid arthritis, autoimmune hemolytic anemia, recurrent miscarriage.

5. Ovarian neoplasm that ≥4 cm in diameter and has no clear pathological diagnosis by surgery.

6. Complicated with adenomyosis, endometriosis confirmed by surgery, ovarian endometriosis cyst ≥2 cm by ultrasound, all kind of malignant tumors or precancerous disease.

7. Untreated hydrosalpinx.

Eliminate or falls off Criteria:

1. Withdraw drug and take appropriate treatment measures if serious adverse events happen during the trial, and subjects will be off.

2. Patients that have bad compliance.

• Minimum Eligible Age: 30 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Sun Yat-sen University

OTHER

Sponsor Role: lead

Responsible Party

Yanhong Deng

doctor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Xing Yang, M.D. & Ph.D.

Role: STUDY_DIRECTOR

The Sixth Affiliated Hospital, Sun Yat-sen University

Central Contacts

Xing Yang, M.D. & Ph.D.

Role: CONTACT

yxing_8358@126.com

020-38048013

References

Sood A, Mohiyiddeen G, Ahmad G, Fitzgerald C, Watson A, Mohiyiddeen L. Growth hormone for in vitro fertilisation (IVF). Cochrane Database Syst Rev. 2021 Nov 22;11(11):CD000099. doi: 10.1002/14651858.CD000099.pub4.

Reference Type: DERIVED

PMID: 34808697 (View on PubMed)

Other Identifiers

newivf20170110

Identifier Type: -

Identifier Source: org_study_id